Revance Therapeutics (RVNC) Announces RT001 REALISE 1 Phase 3 Missed co-Primary, Other Endpoints
Tweet Send to a Friend
Revance Therapeutics, Inc. (Nasdaq: RVNC) reported results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
